RNS Announcements

Final Results

28 June 2023

ProBiotix Health plc (AQSE: PBX), a life sciences business developing probiotics to tackle cardiovascular disease and other lifestyle conditions, announces its audited results for the period ended 31 December 2022, the Company’s inaugural results as a separately listed public company following its flotation on the AQSE Growth Market on 31 March 2022. 


To view a full version of the results in 
PDF format  click here


  • The Company continues to achieve rapid growth with revenue of £1.3m, a 19% increase on FY 2021 (£1.1m*)
  • Cash balance of £1.74m as on 31 December 2022
  • Financially robust with no debt and a strong balance sheet
  • Successful flotation on the AQSE Growth Market on 31 March 2022, raising £2.5m for future development of the Group
  • Third human volunteer study confirming safety and efficacy of LPLDL®
  • Research and clinical study agreements with two UK and one Italian university to examine the role of LPLDL® to improve sleep, and reduce stress and anxiety
  • The appointment of Steen Andersen as Chief Executive Officer of ProBiotix
  • Appointment of Nutraconnect Pte Ltd, based in Singapore, as a new commercialisation partner to develop strategies to expand sales opportunities for both LPLDL® and CholBiome®
  • New customers gained in China, Israel, Hong Kong and Belgium

Post period

  •  Strong order pipeline in 2023 with confirmed orders to first week of June 2023 of £1.1m
  • Launch of CholbiomeCH a dual action bilayer tablet containing phytosterols and LPLDL® to increase opportunities in the US market
  • An enhanced strategy focusing on turnkey solutions and new line extensions
*2021 revenues of £1.1m for ProBiotix Limited, the Company’s principal operating subsidiary

Steen Andersen, CEO of ProBiotix, commented: “Since I became CEO in January 2023, I have developed a strategy which focuses the business on becoming a solutions provider of finished probiotic products in consumer formats, both under our own brands and partner private labels, with the objective of building ProBiotix into a £10m turnover company in the years ahead.  Although the markets are challenging, we have a strong balance sheet with no debt, good sales growth and a healthy cash reserve.

“Given the scale of the market opportunity, the proven efficacy of our existing products, the substantial scope for expansion of our product range and geography and the financial strength of the Company, we look to the future with enthusiasm and high confidence in building a valuable company for shareholders”.


For further information, please contact:

ProBiotix Health plc https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive Contact via Walbrook below
Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker) Tel: 020 7220 9797
Mark Anwyl Tel: 020 7469 0930
Duncan Vasey
Brefo Gyasi
Walbrook PR Ltd [email protected]
Anna Dunphy Mob: 07876 741 001